Korea Arlico PharmLtd Balance Sheet Health
Financial Health criteria checks 3/6
Korea Arlico PharmLtd has a total shareholder equity of ₩89.1B and total debt of ₩46.1B, which brings its debt-to-equity ratio to 51.7%. Its total assets and total liabilities are ₩173.5B and ₩84.4B respectively. Korea Arlico PharmLtd's EBIT is ₩3.1B making its interest coverage ratio 2.7. It has cash and short-term investments of ₩30.8B.
Key information
51.7%
Debt to equity ratio
₩46.08b
Debt
| Interest coverage ratio | 2.7x |
| Cash | ₩30.79b |
| Equity | ₩89.08b |
| Total liabilities | ₩84.40b |
| Total assets | ₩173.48b |
Recent financial health updates
Is Korea Arlico PharmLtd (KOSDAQ:260660) Using Too Much Debt?
Mar 24
Is Korea Arlico PharmLtd (KOSDAQ:260660) A Risky Investment?
Dec 16Recent updates
Is Korea Arlico PharmLtd (KOSDAQ:260660) Using Too Much Debt?
Mar 24Should You Be Adding Korea Arlico PharmLtd (KOSDAQ:260660) To Your Watchlist Today?
Mar 02Korea Arlico PharmLtd's (KOSDAQ:260660) Shareholders Are Down 50% On Their Shares
Feb 12
What Is The Ownership Structure Like For Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)?
Jan 25Should You Use Korea Arlico PharmLtd's (KOSDAQ:260660) Statutory Earnings To Analyse It?
Jan 04Is Korea Arlico PharmLtd (KOSDAQ:260660) A Risky Investment?
Dec 16Are Strong Financial Prospects The Force That Is Driving The Momentum In Korea Arlico Pharm Co.,Ltd.'s KOSDAQ:260660) Stock?
Nov 25Financial Position Analysis
Short Term Liabilities: A260660's short term assets (₩83.6B) exceed its short term liabilities (₩70.3B).
Long Term Liabilities: A260660's short term assets (₩83.6B) exceed its long term liabilities (₩14.1B).
Debt to Equity History and Analysis
Debt Level: A260660's net debt to equity ratio (17.2%) is considered satisfactory.
Reducing Debt: A260660's debt to equity ratio has increased from 51.2% to 51.7% over the past 5 years.
Debt Coverage: A260660's debt is not well covered by operating cash flow (15.5%).
Interest Coverage: A260660's interest payments on its debt are not well covered by EBIT (2.7x coverage).